Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 1179 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

1,179 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,179 programs

Clinical programs

Page 17 of 25

  1. Fazirsiran

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  2. Febuxostat XR

    Takeda

    Gout

    phase 1 small molecule completed

    1 trial

  3. Febuxostat XR

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. Febuxostat XR 80 mg Capsule F1

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. Fucoidan (extract of Laminaria japonica)

    Takeda

    Healthy Volunteers

    phase 1 other completed

    1 trial

  6. HYQVIA

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. Human butyrylcholinesterase (HuBChE) derived from human plasma

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  8. INFS (Intranasal Fentanyl Spray)

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. INV21 Low Dose

    Takeda

    Hand, Foot and Mouth Disease

    phase 1 mab completed

    1 trial

  10. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  11. IXAZOMIB

    Takeda

    Advanced Non-hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  12. IXAZOMIB

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. Icatibant (30 mg)

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  14. Ixazomib

    Takeda

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  15. Ixazomib

    Takeda

    Precursor Cell Lymphoblastic Leukemia-lymphoma

    phase 1 small molecule terminated

    1 trial

  16. Ixazomib

    Takeda

    Glioblastoma

    phase 1 small molecule completed

    1 trial

  17. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  18. Ixazomib

    Takeda

    Light-Chain Amyloidosis

    phase 1 small molecule completed

    1 trial

  19. Ixazomib

    Takeda

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  20. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial

  21. Ixazomib 2.5 mg

    Takeda

    Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  22. Ketamine

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  23. Ketamine

    Takeda

    Ketamine-Induced Brain Activity Changes

    phase 1 small molecule completed

    1 trial

  24. LDX + Venlafaxine XR

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  25. Lanadelumab

    Takeda

    COVID-19 Pneumonia

    phase 1 small molecule terminated

    1 trial

  26. Lanadelumab

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  27. Lansoprazole

    Takeda

    Gastroesophageal Reflux Disease

    phase 1 small molecule completed

    2 trials

  28. Lanthanum carbonate Granule Formulation

    Takeda

    End Stage Renal Disease

    phase 1 small molecule completed

    1 trial

  29. Lisdexamfetamine Dimesylate

    Takeda

    Healthy

    phase 1 small molecule terminated

    1 trial

  30. Lisdexamfetamine Dimesylate

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  31. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    Attention-Deficit Hyperactivity Disorder

    phase 1 small molecule completed

    1 trial

  32. Lubiprostone

    Takeda

    Chronic Constipation, Methanogenesis

    phase 1 small molecule completed

    1 trial

  33. Lubiprostone

    Takeda

    Other Constipation

    phase 1 small molecule completed

    1 trial

  34. MEDI1341

    Takeda

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

  35. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  36. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  37. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  38. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  39. MLN1202

    Takeda

    Healthy Japanese and Caucasian Male Adults

    phase 1 small molecule terminated

    1 trial

  40. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  41. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  42. MLN3126

    Takeda

    Safety

    phase 1 small molecule terminated

    1 trial

  43. MLN3126

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  44. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  45. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  46. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  47. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  48. MT203 80 mg or matching Placebo

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.